CG Oncology, Inc. (NASDAQ: CGON) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $50.00 price target on the stock.
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates [Yahoo! Finance]
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value [Seeking Alpha]
CG Oncology, Inc. (NASDAQ: CGON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.